520 related articles for article (PubMed ID: 19057660)
41. Echinocandin resistance due to simultaneous FKS mutation and increased cell wall chitin in a Candida albicans bloodstream isolate following brief exposure to caspofungin.
Imtiaz T; Lee KK; Munro CA; MacCallum DM; Shankland GS; Johnson EM; MacGregor MS; Bal AM
J Med Microbiol; 2012 Sep; 61(Pt 9):1330-1334. PubMed ID: 22653922
[TBL] [Abstract][Full Text] [Related]
42. Caspofungin: when and how? The microbiologist's view.
Mayr A; Aigner M; Lass-Flörl C
Mycoses; 2012 Jan; 55(1):27-35. PubMed ID: 21668518
[TBL] [Abstract][Full Text] [Related]
43. Interface of Candida albicans biofilm matrix-associated drug resistance and cell wall integrity regulation.
Nett JE; Sanchez H; Cain MT; Ross KM; Andes DR
Eukaryot Cell; 2011 Dec; 10(12):1660-9. PubMed ID: 21666076
[TBL] [Abstract][Full Text] [Related]
44. Reshuffling of Aspergillus fumigatus cell wall components chitin and β-glucan under the influence of caspofungin or nikkomycin Z alone or in combination.
Verwer PE; van Duijn ML; Tavakol M; Bakker-Woudenberg IA; van de Sande WW
Antimicrob Agents Chemother; 2012 Mar; 56(3):1595-8. PubMed ID: 22203603
[TBL] [Abstract][Full Text] [Related]
45. Rapid redistribution of phosphatidylinositol-(4,5)-bisphosphate and septins during the Candida albicans response to caspofungin.
Badrane H; Nguyen MH; Blankenship JR; Cheng S; Hao B; Mitchell AP; Clancy CJ
Antimicrob Agents Chemother; 2012 Sep; 56(9):4614-24. PubMed ID: 22687514
[TBL] [Abstract][Full Text] [Related]
46. Acquired resistance to echinocandins in Candida albicans: case report and review.
Baixench MT; Aoun N; Desnos-Ollivier M; Garcia-Hermoso D; Bretagne S; Ramires S; Piketty C; Dannaoui E
J Antimicrob Chemother; 2007 Jun; 59(6):1076-83. PubMed ID: 17468115
[TBL] [Abstract][Full Text] [Related]
47. Mnn10 Maintains Pathogenicity in Candida albicans by Extending α-1,6-Mannose Backbone to Evade Host Dectin-1 Mediated Antifungal Immunity.
Zhang SQ; Zou Z; Shen H; Shen SS; Miao Q; Huang X; Liu W; Li LP; Chen SM; Yan L; Zhang JD; Zhao JJ; Xu GT; An MM; Jiang YY
PLoS Pathog; 2016 May; 12(5):e1005617. PubMed ID: 27144456
[TBL] [Abstract][Full Text] [Related]
48. Novel structural features in Candida albicans hyphal glucan provide a basis for differential innate immune recognition of hyphae versus yeast.
Lowman DW; Greene RR; Bearden DW; Kruppa MD; Pottier M; Monteiro MA; Soldatov DV; Ensley HE; Cheng SC; Netea MG; Williams DL
J Biol Chem; 2014 Feb; 289(6):3432-43. PubMed ID: 24344127
[TBL] [Abstract][Full Text] [Related]
49. A CO
Avelar GM; Pradhan A; Ma Q; Hickey E; Leaves I; Liddle C; Rodriguez Rondon AV; Kaune A-K; Shaw S; Maufrais C; Sertour N; Bain JM; Larcombe DE; de Assis LJ; Netea MG; Munro CA; Childers DS; Erwig LP; Brown GD; Gow NAR; Bougnoux M-E; d'Enfert C; Brown AJP
mBio; 2024 Feb; 15(2):e0189823. PubMed ID: 38259065
[TBL] [Abstract][Full Text] [Related]
50. Calcineurin controls drug tolerance, hyphal growth, and virulence in Candida dubliniensis.
Chen YL; Brand A; Morrison EL; Silao FG; Bigol UG; Malbas FF; Nett JE; Andes DR; Solis NV; Filler SG; Averette A; Heitman J
Eukaryot Cell; 2011 Jun; 10(6):803-19. PubMed ID: 21531874
[TBL] [Abstract][Full Text] [Related]
51. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
52. Dectin-1 mediates macrophage recognition of Candida albicans yeast but not filaments.
Gantner BN; Simmons RM; Underhill DM
EMBO J; 2005 Mar; 24(6):1277-86. PubMed ID: 15729357
[TBL] [Abstract][Full Text] [Related]
53. In vitro antifungal activities and in vivo efficacies of 1,3-beta-D-glucan synthesis inhibitors L-671,329, L-646,991, tetrahydroechinocandin B, and L-687,781, a papulacandin.
Bartizal K; Abruzzo G; Trainor C; Krupa D; Nollstadt K; Schmatz D; Schwartz R; Hammond M; Balkovec J; Vanmiddlesworth F
Antimicrob Agents Chemother; 1992 Aug; 36(8):1648-57. PubMed ID: 1416847
[TBL] [Abstract][Full Text] [Related]
54. Evasion of Immune Surveillance in Low Oxygen Environments Enhances Candida albicans Virulence.
Lopes JP; Stylianou M; Backman E; Holmberg S; Jass J; Claesson R; Urban CF
mBio; 2018 Nov; 9(6):. PubMed ID: 30401781
[TBL] [Abstract][Full Text] [Related]
55. Sequential therapy with caspofungin and fluconazole for Candida albicans infection.
Barchiesi F; Spreghini E; Baldassarri I; Marigliano A; Arzeni D; Giannini D; Scalise G
Antimicrob Agents Chemother; 2004 Oct; 48(10):4056-8. PubMed ID: 15388480
[TBL] [Abstract][Full Text] [Related]
56. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates.
Park S; Kelly R; Kahn JN; Robles J; Hsu MJ; Register E; Li W; Vyas V; Fan H; Abruzzo G; Flattery A; Gill C; Chrebet G; Parent SA; Kurtz M; Teppler H; Douglas CM; Perlin DS
Antimicrob Agents Chemother; 2005 Aug; 49(8):3264-73. PubMed ID: 16048935
[TBL] [Abstract][Full Text] [Related]
57. Dectin-1 is required for beta-glucan recognition and control of fungal infection.
Taylor PR; Tsoni SV; Willment JA; Dennehy KM; Rosas M; Findon H; Haynes K; Steele C; Botto M; Gordon S; Brown GD
Nat Immunol; 2007 Jan; 8(1):31-8. PubMed ID: 17159984
[TBL] [Abstract][Full Text] [Related]
58. Proteomic analysis of proteins released from growth-arrested Candida albicans following exposure to caspofungin.
Kelly J; Kavanagh K
Med Mycol; 2010 Jun; 48(4):598-605. PubMed ID: 20392151
[TBL] [Abstract][Full Text] [Related]
59. Addition of caspofungin to fluconazole does not improve outcome in murine candidiasis.
Graybill JR; Bocanegra R; Najvar LK; Hernandez S; Larsen RA
Antimicrob Agents Chemother; 2003 Jul; 47(7):2373-5. PubMed ID: 12821503
[TBL] [Abstract][Full Text] [Related]
60. Immune recognition of Candida albicans beta-glucan by dectin-1.
Gow NA; Netea MG; Munro CA; Ferwerda G; Bates S; Mora-Montes HM; Walker L; Jansen T; Jacobs L; Tsoni V; Brown GD; Odds FC; Van der Meer JW; Brown AJ; Kullberg BJ
J Infect Dis; 2007 Nov; 196(10):1565-71. PubMed ID: 18008237
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
